Karuna Therapeutics, Inc.
NASDAQ:KRTX
329.83 (USD) • At close March 15, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0.654 | 10.637 | 36.964 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.701 | 1.112 | 0.506 | 0.145 | 0.058 | 0 | 0 |
| Gross Profit
| -1.047 | 9.525 | 36.458 | -0.145 | -0.058 | 0 | 0 |
| Gross Profit Ratio
| -1.601 | 0.895 | 0.986 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 364.101 | 224.247 | 128.2 | 43.408 | 24.536 | 11.536 | 3.616 |
| General & Administrative Expenses
| 131.33 | 76.066 | 52.617 | 28.408 | 20.869 | 2.974 | 1.19 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 131.33 | 76.066 | 52.617 | 28.408 | 20.869 | 2.974 | 1.19 |
| Other Expenses
| 0.588 | 0.58 | 0.254 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 495.431 | 300.313 | 180.817 | 71.816 | 45.405 | 14.51 | 4.806 |
| Operating Income
| -494.777 | -289.676 | -143.853 | -71.816 | -45.405 | -14.51 | -4.806 |
| Operating Income Ratio
| -756.54 | -27.233 | -3.892 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 61.767 | 14.758 | 0.054 | 3.305 | 1.448 | -3.002 | -1.226 |
| Income Before Tax
| -433.01 | -274.918 | -143.799 | -68.511 | -43.957 | -17.512 | -6.032 |
| Income Before Tax Ratio
| -662.095 | -25.845 | -3.89 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.67 | 1.418 | 0.006 | 0.043 | 0.887 | -0.419 | 1.171 |
| Net Income
| -433.68 | -276.336 | -143.805 | -68.554 | -44.844 | -17.512 | -6.032 |
| Net Income Ratio
| -663.119 | -25.979 | -3.89 | 0 | 0 | 0 | 0 |
| EPS
| -11.73 | -8.74 | -4.94 | -2.59 | -3.75 | -1.61 | -0.81 |
| EPS Diluted
| -11.73 | -8.74 | -4.94 | -2.59 | -3.75 | -1.61 | -0.81 |
| EBITDA
| -493.076 | -289.676 | -143.151 | -68.511 | -42.877 | -14.479 | -4.805 |
| EBITDA Ratio
| -753.939 | -27.233 | -3.873 | 0 | 0 | 0 | 0 |